Encore Vision’s treatment is directed at the biochemical cause of presbyopia, the cross-links that form with age and result in increased lens stiffness. The Company’s technology is based on using the already present endogenous reducing enzymes in the human lens to work with the Company’s proprietary small molecule prodrug to break the cross-links and return the lens to a more natural state. The Company has proven in extensive animal testing that its proprietary formulation will penetrate the cornea and deliver therapeutic prodrug concentrations into the aqueous humor where these same levels have shown in vivo to soften otherwise hardened lenses.
The Encore Vision treatment approach should not disrupt the fiber structure of the lens or any natural proteins, and therefore will not likely result in optical distortions which can result from mechanical or laser treatment approaches.
Since no damage will occur to crystalline lens proteins or cell structures, the Encore Vision approach is not traumatic and the Company believes it will be much safer than other invasive biomechanical treatment approaches currently being explored.
The Encore Vision treatment regiment in development is instilling comfortable eye drops into one’s eyes to soften the lens and restore accommodation and near vision focal power. The Company’s goal is to develop a treatment that will demonstrate measurable results within 30 days of beginning therapy. The treatment is doctor and patient friendly. The treatment restores the natural ability of human crystalline lens to reduce aberrant bonds, cross-links, thus regaining lens flexibility and softness, thereby restoring accommodation and focal power.